PYRUKYND, a pyruvate kinase activator, remains the flagship product with multi-billion-dollar potential. Agios is targeting a U.S. approval for thalassemia by September 7, 2025, and a sickle cell ...

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today reported business highlights and financial ...

So-called "Magnificent Seven" stocks Amazon, Meta Platforms, and Nvidia remain great long-term picks. The Trade Desk's share ...

Agios Pharmaceuticals Inc (AGIO) reports a 6% revenue increase and outlines promising pipeline developments, despite facing ...

You’ve likely heard people mention that they have inherited certain health conditions from their family. These are known as ...

Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their ...

The following is a summary of “Evaluated NSUN3 in reticulocytes from HbH-CS disease that reflects cellular stress in ...

Punjab Information Minister Azma Bokhari visited Sundas Foundation in Lahore, where she spent time with children battling ...

The requirement is part of the newly passed Punjab Thalassemia Prevention Act 2025, aimed at curbing the spread of hereditary diseases. According to the law, all students applying for admission ...

As scientists explore treating genetic disorders before birth, the promise of foetal gene therapy is growing—but there are ...

Analysts anticipate Vertex Pharmaceuticals to report an earnings per share (EPS) of $4.31. Anticipation surrounds Vertex Pharmaceuticals's announcement, with investors hoping to hear about both ...

Fulcrum Therapeutics, Inc.’s FULC share price has surged by 7.37%, which has investors questioning if this is right time to ...